GLP-1 Medications: A New Frontier in Treating Binge Eating Disorder

Last Updated: MARCH 2026

Binge Eating Disorder (BED) is a serious and complex eating disorder, distinct from occasional overeating. For many struggling with BED, the relentless cycle of consuming large amounts of food and feeling a loss of control is debilitating. Emerging evidence suggests a new class of medications, GLP-1 receptor agonists, originally approved for type 2 diabetes and obesity, may offer a novel therapeutic pathway. In a retrospective cohort study published in The Journal of Clinical Psychiatry in 2023, semaglutide significantly lowered Binge Eating Scale (BES) scores from an average of 25.4 (±7.8) at baseline to 15.6 (±7.6) after treatment (p < 0.001), indicating a marked reduction in binge eating severity (Richards et al., 2023). This finding underscores the potential of GLP-1s to address core symptoms of BED.

Understanding Binge Eating Disorder

Binge Eating Disorder is the most common eating disorder in the United States, affecting an estimated 2.8% of adults over their lifetime. It is characterized by recurrent episodes of eating unusually large amounts of food, often very quickly and to the point of discomfort. Crucially, these episodes are accompanied by a feeling of a loss of control. Unlike bulimia nervosa, individuals with BED do not regularly engage in compensatory behaviors such as purging, excessive exercise, or fasting.

The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), outlines specific criteria for BED, including:

• Recurrent episodes of binge eating.
• Binge eating episodes associated with three (or more) of the following:
  • Eating much more rapidly than normal.
  • Eating until feeling uncomfortably full.
  • Eating large amounts of food when not feeling physically hungry.
  • Eating alone because of feeling embarrassed by how much one is eating.
  • Feeling disgusted with oneself, depressed, or very guilty afterward.
• Marked distress regarding binge eating.
• The binge eating occurs, on average, at least once a week for 3 months.
• The binge eating is not associated with the recurrent use of inappropriate compensatory behavior as in bulimia nervosa and does not occur exclusively during the course of bulimia nervosa or anorexia nervosa.

BED is not merely a behavioral problem but a neurobiological one, often co-occurring with depression, anxiety disorders, and obesity. Its origins are multifaceted, involving genetic predispositions, psychological factors, and disruptions in brain circuits that regulate appetite, satiety, and reward.

How GLP-1s Intervene in Compulsive Eating

GLP-1 receptor agonists, such as semaglutide (Wegovy, Ozempic, Rybelsus) and tirzepatide (Zepbound, Mounjaro), mimic the action of a natural hormone called glucagon-like peptide-1. This hormone plays a critical role in several physiological processes relevant to managing both weight and compulsive eating behaviors.

The mechanisms by which GLP-1s exert their influence on BED symptoms are multifaceted:

1. Appetite Suppression and Satiety: GLP-1s act on receptors in the brain, particularly in the hypothalamus, which is the control center for hunger and satiety. By activating these receptors, GLP-1s signal to the brain that the body is full and satisfied, reducing overall appetite and making it easier to consume smaller portions. This directly counteracts the uncontrolled hunger often experienced during a binge episode.
2. Delayed Gastric Emptying: These medications slow down the rate at which food leaves the stomach. This effect prolongs the feeling of fullness, further contributing to reduced food intake and making it less likely for an individual to feel hungry shortly after eating. For someone prone to binges, this extended satiety can be a powerful deterrent.
3. Impact on Reward Pathways and “Food Noise”: Beyond physical hunger, GLP-1s appear to influence the brain’s reward system, which is heavily implicated in cravings and the compulsive drive to eat palatable foods. Many patients on GLP-1s report a significant reduction in “food noise”—the constant preoccupation with food, planning meals, and battling cravings. This mental quietude can be transformative for individuals with BED, freeing them from the constant internal battle over food choices. While the precise neurochemical mechanisms are still being elucidated, this effect is hypothesized to involve modulation of dopamine pathways in areas like the nucleus accumbens, reducing the hedonic “liking” and motivational “wanting” of food.
4. Blood Sugar Regulation: Although less directly linked to the compulsive aspect of BED, GLP-1s also improve blood sugar control. Stable blood sugar levels can help prevent spikes and crashes that sometimes trigger hunger or cravings, contributing to overall metabolic stability that can support healthier eating patterns.

By targeting these interconnected pathways, GLP-1s offer a comprehensive approach to managing BED symptoms, moving beyond simple caloric restriction to addressing the underlying neurobiological drivers of compulsive eating.

Clinical Evidence for GLP-1s in BED

While GLP-1 medications are not yet FDA-approved specifically for Binge Eating Disorder, their efficacy in promoting weight loss and suppressing appetite has led to increasing interest in their off-label use for this condition. The Richards et al. (2023) retrospective study provides some of the most compelling early data. The study involved a cohort of patients who received semaglutide (administered once weekly) for various indications, including obesity and comorbid BED. Their findings showed a statistically significant reduction in BES scores, reflecting a substantial decrease in binge eating behaviors.

“We noted that patients described a ‘freedom’ from food preoccupation that allowed for greater control over their eating behaviors and improved quality of life,” noted the authors in their discussion of the study’s implications (Richards et al., 2023).

It’s important to frame these findings within the context of scientific rigor. Retrospective studies, while valuable for generating hypotheses and identifying trends, are limited by their design. They rely on existing medical records and do not involve randomized assignment to treatment or placebo, meaning other factors could contribute to the observed improvements. Large-scale, randomized controlled trials (RCTs) specifically designed to evaluate GLP-1s for BED are needed to confirm these preliminary findings and establish definitive efficacy and safety for this indication. These trials would provide robust data on specific outcomes, optimal dosing, and long-term effects.

For context, the only FDA-approved medication specifically for Binge Eating Disorder (and moderate-to-severe eating disorder in adults) is lisdexamfetamine dimesylate (Vyvanse), approved in 2015 (FDA, 2015). This medication is a stimulant that works differently, often targeting impulsivity and attention, and comes with its own set of considerations.

The “Food Noise” Phenomenon: A Game Changer for Patients

The anecdotal and emerging clinical evidence surrounding GLP-1s and BED frequently highlights the reduction in “food noise” as a pivotal benefit. For individuals with BED, the internal monologue about food—what to eat, when to eat, resisting urges, planning binges—can be relentless and exhausting. This constant mental burden can make daily life challenging, consuming significant mental energy and contributing to anxiety and depression.

GLP-1 medications appear to quiet this “food noise,” providing a sense of mental freedom many patients have never experienced. This quieting effect allows individuals to engage more fully in their lives, focus on activities beyond food, and apply cognitive-behavioral strategies with greater success. Comedian Margaret Cho, for instance, has publicly shared her experience, stating that GLP-1 medications have been a “lifesaver” in managing the “self-soothing” cravings associated with her binge eating disorder. Such personal accounts, while not scientific evidence, illustrate the profound subjective impact these medications can have on the lived experience of BED.

GLP-1 Medications: What’s Available and What’s Coming

Several GLP-1 receptor agonists are currently available, primarily approved for type 2 diabetes and/or chronic weight management. Their potential role in BED treatment stems from their effects on appetite and satiety.

Note: Use of these medications for Binge Eating Disorder is currently off-label and should be discussed with a qualified healthcare provider.

The landscape of GLP-1s is rapidly evolving:

• Oral Semaglutide for Weight Loss: While Rybelsus (oral semaglutide) is available for type 2 diabetes, Novo Nordisk has indicated plans to launch a higher-dose oral semaglutide (25 mg) specifically for weight loss in the U.S. in 2026. This would offer a needle-free option for those who prefer pills.
• CagriSema (Cagrilintide + Semaglutide): Novo Nordisk applied for FDA approval of this novel combination drug in December 2025. CagriSema combines semaglutide with cagrilintide, an amylin analog. Amylin is another gut hormone that contributes to satiety and glucose control. Early data suggests CagriSema could offer even greater weight loss potential than existing GLP-1s alone, potentially further enhancing its utility for conditions like BED.

These advancements signify a future with more potent and varied GLP-1 options, potentially expanding treatment avenues for those grappling with BED.

Considerations and Risks

While GLP-1s offer significant promise, they are not without considerations and potential side effects.

Common Side Effects:

• Nausea
• Vomiting
• Diarrhea
• Constipation
• Abdominal pain

These gastrointestinal side effects are typically mild to moderate and often subside as the body adjusts to the medication, especially with slow dose titration.

Serious, Less Common Risks: *